[1] |
WANG Kun, XU Peipei, ZHOU Lanlan, LU Sheng.
Mechanism of neuroprotective effect of ginsenoside Rg1 regulating Epac1/Rap1 signaling pathway in rats with ischemic stroke
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 721-727.
|
[2] |
LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin.
Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
|
[3] |
QIN Wenxiu, XU Junfeng, YANG Ting, WANG Pingfei.
Research progress on signaling pathway of tanshinoneIIA in treatment of nerve injury after ischemic stroke
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 705-713.
|
[4] |
ZHU Li, WEI Bing, LIAO Shi'e, ZHANG Chao, ZHENG Xiaoyu, LIU Yajun.
Effects of single nucleotide polymorphism of drug metabolizing enzyme cytochrome P450 on the efficacy of inhaled cortisol hormone in asthmatic children
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 536-543.
|
[5] |
ZHANG Zhiying, JIN Xiuhong, ZHANG Xiaoning, ZHANG Xiangfeng, LUO Qinglin, ZHANG Songlin.
Clinical study of TBX21 and ADCY9 polymorphisms in the develop- ment of childhood asthma
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 407-412.
|
[6] |
NING Sisi, ZHAO Yuhong, YAN Lei, TANG Minna, ZHANG Ningzhi, ZHANG Yongqiao, CUI Zhaoqiang.
Controversies over the targets of controlling blood pressure in hyper- tensive patients with chronic kidney disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 463-467.
|
[7] |
SHEN Chang, AI Kelong, HU Changping.
Research progress in the regulation of hypoxic pulmonary hypertension by hypoxia-inducible factor-1 signaling pathway
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 114-120.
|
[8] |
CHEN Wengang, YIN Qin, ZHANG Weiwei, ZHOU Lulu, KOU Wanqing, YUAN Xiaolong.
Distributions of MTHFR gene polymorphism and its correlation with blood Hcy in patients with hypertension in southern Anhui province
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 768-774.
|
[9] |
LIANG Meifang, CHEN Qingzhuang, YANG Peiqun, WANG Yong.
Efficacy and safety of generic and branded atorvastatin in patients with ischemic stroke/transient ischemic attack: A real-world study
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 785-792.
|
[10] |
WU Yuanzhu, LIU Jun, YANG Kui, PENG Jing, LUAN Jiajie, WEI Jun, ZHANG Dafa, SONG Shuai, YUAN Xiaolong, WANG Zhongfang, ZHANG Nianbao, XIE Dan, JIANG Peng, FAN Jie.
Distribution of CYP2C9*3 and VKORC1-1639G>A gene polymorphism in Anhui Han population and their influence on the stable dose of warfarin
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 652-659.
|
[11] |
ZHANG Ningzhi, ZHAO Yuhong, TANG Minna, ZHANG Yongqiao, NING Sisi, CUI Zhaoqiang.
Application of chronopharmacology in the hypertension treatment
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 418-422.
|
[12] |
CUI Sumei, CUI Zhaoqiang.
Application of β-blockers for hypertension
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 423-427.
|
[13] |
LI Yuanfang, CUI Zhaoqiang.
Treatment of hypertension complicated with hyperuricemia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 428-432.
|
[14] |
XU Jianfei, LIN Li.
Research progress in pharmacological and non-pharmacological treatments of hypertension
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 433-441.
|
[15] |
KUAI Zheng, ZHANG Xiaoyi, ZOU Yunzeng.
Angiotensin receptor neprilysin inhibitor in elderly with hypertension
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 442-445.
|